Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NO_LONGER_AVAILABLE
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Screening: The patient will start the program once the Screening assessments are completed and the patient is qualified for participation.
* Treatment: Additional assessments, physical examinations, and dosage changes will be clinically determined by the treating physician.
Patients will enter this program on the same dose of perampanel that they were receiving at the end of their participation in previous study. Doses of perampanel and of concomitant anti-epileptic drugs (AEDs) can be adjusted (i.e., added,removed, or changed in dose) based on clinical judgment.
Treatment will be prescribed as long as clinically appropriate according to the judgement of the treating physician and the approved Summary of Product Characteristics (SmPC).
The program will complete in a staggered fashion, country by country, as and when perampanel becomes commercially available for the treatment of POS in each country.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Extended Access Program (EAP) for Perampanel
NCT02307578
A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures
NCT01618695
To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
NCT00699582
A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)
NCT00903786
Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
NCT00735397
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Perampanel
Patients will enter this program on the same dose of perampanel that they were receiving at the end of their participation in Studies 207, 307, or 235. Doses of perampanel and of concomitant anti-epileptic drugs (AEDs) can be adjusted based on clinical judgment. A minimum daily dose permitted will be 12 mg per day. Treatment will be prescribed as long as clinically appropriate according to the judgment of the treating physician and the approved summary of Product Characteristics (SmPC). Tablets will be available in strengths of 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg. Patients will be instructed to take their perampanel tablets once daily, by mouth, before bedtime, and with food.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who provide informed consent where applicable per local requirements.
* Female patients of childbearing potential must agree for the duration of the program and for a period of at least 1 month following last dose of perampanel to be abstinent or to commit to the consistent and correct use of a medically acceptable method of birth control (e.g., a double-barrier method \[condom plus spermicide, condom plus diaphragm with spermicide\])
Exclusion Criteria
* Female patients who are lactating, pregnant, or planning to become pregnant
12 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eisai Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fundacion Cerebro Y Mente
Mendoza, Mendoza Province, Argentina
Hospital General De Agudos José María Ramos Mejia
Buenos Aires, , Argentina
Buenos Aires, , Argentina
Centro De Estudio Y Tratamiento De La Epilepsia Y Sueno - Cetes S.A.
Córdoba, , Argentina
Rosario, , Argentina
San José Guaymallén, , Argentina
San Miguel de Tucumán, , Argentina
St Vincent's Hospital Melbourne
Fitzroy, , Australia
Fitzroy, , Australia
Clinical Trials, Epilepsy Research Centre, Melbourne Brain Centre
Heidelberg, , Australia
Royal Melbourne Hospital
Parkville, , Australia
Victoria, , Australia
Uz Antwerpen
Edegem, , Belgium
Edegem, , Belgium
Uz Gent
Ghent, , Belgium
Ghent, , Belgium
Ottignies, , Belgium
Foothills Medical Center
Calgary, Albert, Canada
London Health Sciences Center
London, Ontario, Canada
Youthdale Treatment Centers
Toronto, Ontario, Canada
Calgary, , Canada
London, Ontario, , Canada
Puente Alto, , Chile
Hospital Dr. Sótero Del Río
Santiago, , Chile
Santiago, , Chile
Hospital Base Valdivia Servicio De Neurología
Valdivia, , Chile
Valdivia, , Chile
Fakultni Nemocnice U Sv. Anny V Brne
Brno, , Czechia
Fakultni Nemocnice Hradec Kralove
Hradec Králové, , Czechia
Ostrava, , Czechia
Fakultni Nemocnice V Motole
Prague, , Czechia
Laagri, , Estonia
West Tallinn Central Hospital
Tallinn, , Estonia
Oy Neurodiagnostika Ap
Tallinn, , Estonia
Tallinn Children's Hospital
Tallinn, , Estonia
Tartu University Hospital
Tartu, , Estonia
Vantaa, , Finland
Greece, , Greece
Kwai Chung, , Hong Kong
Budapest, , Hungary
Barzilai Medical Center
Ashkelon, , Israel
Rambam Medical Center
Haifa, , Israel
Haifa, , Israel
Edith Wolfson Medical Center
Holon, , Israel
Netanya, , Israel
Azienda Ospedaliera Universitaria Federico Ii
Napoli, , Italy
Napoli, , Italy
Prague, , Latvia
Childrens Clinical University Hospital
Riga, , Latvia
Riga, , Latvia
Outpatient Clinic 'Valmieras Veselibas Centrs'
Valmiera, , Latvia
Hospital Of Lithuanian University Of Health Sciences Kaunas Clinics
Kaunas, , Lithuania
Kaunas, , Lithuania
Klaipeda University Hospital
Klaipėda, , Lithuania
Vilnius University Hospital Santariskes Clinics
Vilnius, , Lithuania
University Malaya Medical Centre
Kuala Lumpur, , Malaysia
Petaling Jaya, , Malaysia
Haarlem, , Netherlands
Kempenhaeghe
Heeze, , Netherlands
Stichting Epilepsie Instellingen Nederland
Hoofddorp, , Netherlands
Akademickie Centrum Kliniczne - Szpital Akademii Medycznej W Gdansku
Gdansk, , Poland
Gdansk, , Poland
Albacete, , Spain
Hospital Universitario San Cecilio
Granada, , Spain
Granada, , Spain
Fundacion Jimenez Diaz
Madrid, , Spain
Hospital Clinico San Carlos
Madrid, , Spain
Madrid, , Spain
Hospital Universitari I Politècnis La Fe Bulevar Sur
Valencia, , Spain
Valencia, , Spain
Dawan, , Taiwan
Tainan City, , Taiwan
Taoyuan District, , Taiwan
King Chulalongkorn Memorial Hospital, Chulalongkorn University
Bangkok, , Thailand
Phramongkutklao Hospital
Bangkok, , Thailand
Bangplee, , Thailand
Maharaj Nakorn Chiang Mai, Chiang Mai University
Chiang Mai, , Thailand
Srinagarind Hospital
Khonkaen, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E2007-G000-401
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.